MARKET

PTN

PTN

Palatin Tech
AMEX

Real-time Quotes | Nasdaq Last Sale

0.3645
+0.0145
+4.14%
After Hours: 0.3500 -0.0145 -3.98% 19:58 05/27 EDT
OPEN
0.3680
PREV CLOSE
0.3500
HIGH
0.3681
LOW
0.3560
VOLUME
153.78K
TURNOVER
0
52 WEEK HIGH
0.9600
52 WEEK LOW
0.3150
MARKET CAP
84.48M
P/E (TTM)
-2.3202
1D
5D
1M
3M
1Y
5Y
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Misses Revenue Estimates
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 0% and 62.76%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/17 12:45
Recap: Palatin Technologies Q3 Earnings
  Palatin Technologies (AMEX:PTN) reported its Q3 earnings results on Tuesday, May 17, 2022 at 07:30 AM. Here's what investors need to know about the announcement. Earnings Palatin Technologies reported in-line EPS of $-0.03 versus an estimate of $-0.03.
Benzinga · 05/17 11:47
BRIEF-Palatin Reports Third Quarter Fiscal Year 2022 Financial Results And Provides Corporate Update
reuters.com · 05/17 11:43
Palatin Technologies Q3 EPS $(0.03), Inline, Sales $216.10K Miss $350.00K Estimate
Palatin Technologies (AMEX:PTN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 50 percent decrease over losses of $(0.02) per share from the same period last year. The
Benzinga · 05/17 11:38
-- Earnings Flash (PTN) PALATIN TECHNOLOGIES Posts Q3 Revenue $216,097
MT Newswires · 05/17 07:48
Palatin Tech Q3 2022 Earnings Preview
Palatin Tech (NYSE:PTN) is scheduled to announce Q3 earnings results on Tuesday, May 17th, before market open. The consensus EPS Estimate is -$0.03 (-50.0% Y/Y) and the consensus Revenue Estimate
Seekingalpha · 05/16 16:39
Notable earnings before Tuesday's open
AER, ALLT, BPTH, OTCPK:ENGIY, OTCQB:GAXY, HD, HUYA, OTCQX:IMBBY, JD, JMIA, KMDA, MDWD, OBSV, ONON, PTN, REE, RSKD, SE, VBLT, VOD, WMT, XNET For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 05/16 16:23
A Preview Of Palatin Technologies's Earnings
Palatin Technologies (AMEX:PTN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-17. Here's what investors need to know before the announcement. Analysts estimate that Palatin Technologies will report an earnings per share (EPS) of $...
Benzinga · 05/16 15:04
More
No Data
Learn about the latest financial forecast of PTN. Analyze the recent business situations of Palatin Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

66.67%Strong Buy
33.33%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PTN stock price target is 3.333 with a high estimate of 5.00 and a low estimate of 2.000.
High5.00
Average3.333
Low2.000
Current 0.3645
EPS
Actual
Estimate
-0.05-0.04-0.02-0.01
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 98
Institutional Holdings: 44.69M
% Owned: 19.28%
Shares Outstanding: 231.77M
TypeInstitutionsShares
Increased
32
4.81M
New
20
1.36M
Decreased
17
1.34M
Sold Out
6
1.12M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
No Data
No Data
About PTN
Palatin Technologies, Inc. (Palatin), is a biopharmaceutical company. Palatin is focused on developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Palatin product candidates are targeted receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions and tissue homeostasis, and therapeutic agents modulating this system have potential to treat cardiovascular and fibrotic diseases. Palatin lead product includes Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its other product line includes PL9643 for dry eye disease and anti-inflammatory ocular indications and Oral PL8177 for inflammatory bowel diseases.

Webull offers kinds of Palatin Technologies, Inc. stock information, including AMEX:PTN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PTN stock methods without spending real money on the virtual paper trading platform.